CA2895526C - Radiosensitizer compounds for use in combination with radiation - Google Patents

Radiosensitizer compounds for use in combination with radiation Download PDF

Info

Publication number
CA2895526C
CA2895526C CA2895526A CA2895526A CA2895526C CA 2895526 C CA2895526 C CA 2895526C CA 2895526 A CA2895526 A CA 2895526A CA 2895526 A CA2895526 A CA 2895526A CA 2895526 C CA2895526 C CA 2895526C
Authority
CA
Canada
Prior art keywords
cancer
compound
radiation
combination
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2895526A
Other languages
English (en)
French (fr)
Other versions
CA2895526A1 (en
Inventor
Qing-bin LU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2895526A1 publication Critical patent/CA2895526A1/en
Application granted granted Critical
Publication of CA2895526C publication Critical patent/CA2895526C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/52—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2895526A 2012-12-20 2013-12-20 Radiosensitizer compounds for use in combination with radiation Active CA2895526C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261797983P 2012-12-20 2012-12-20
US61/797,983 2012-12-20
PCT/CA2013/051005 WO2014094178A1 (en) 2012-12-20 2013-12-20 Radiosensitizer compounds for use in combination with radiation

Publications (2)

Publication Number Publication Date
CA2895526A1 CA2895526A1 (en) 2014-06-26
CA2895526C true CA2895526C (en) 2021-08-24

Family

ID=50977492

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2895526A Active CA2895526C (en) 2012-12-20 2013-12-20 Radiosensitizer compounds for use in combination with radiation

Country Status (10)

Country Link
US (1) US9655965B2 (enExample)
EP (1) EP2935215B1 (enExample)
JP (1) JP6321673B2 (enExample)
KR (1) KR102278760B1 (enExample)
CN (1) CN105164107B (enExample)
AU (1) AU2013362757B2 (enExample)
BR (1) BR112015014855A2 (enExample)
CA (1) CA2895526C (enExample)
MX (1) MX2015008010A (enExample)
WO (1) WO2014094178A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102307387B1 (ko) 2013-10-08 2021-09-30 큉-빈 루 표적화된 화학요법에 사용하기 위한 비­백금­기반 항암 화합물
JP6927882B2 (ja) * 2015-04-02 2021-09-01 プロキシマジェン，リミティド ライアビリティ カンパニー 癌の新治療法
CN106045932B (zh) * 2016-06-06 2018-05-15 浙江省肿瘤医院 一种具有放射增敏作用的化合物及其应用
JP6955243B2 (ja) * 2017-02-24 2021-10-27 学校法人北里研究所 ネクローシスの検出キット及びその使用
JP7098054B2 (ja) * 2018-05-30 2022-07-08 ファロス・アイバイオ・カンパニー・リミテッド ２，３，５－置換されたチオフェン化合物の放射線治療増進用途
WO2021224186A1 (en) * 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
CN114478524A (zh) * 2022-03-15 2022-05-13 江苏省肿瘤医院 1,8-萘啶类化合物及其应用
CN114560799A (zh) * 2022-03-15 2022-05-31 江苏省肿瘤医院 腈基取代苯基类化合物及其应用
CN120501862B (zh) * 2025-07-18 2025-10-10 四川大学华西医院 一种能够放射增敏和防护放射性损伤的双效化合物、包含其的组合物及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5011451B1 (enExample) * 1969-05-05 1975-05-01
GB1363735A (en) * 1970-10-23 1974-08-14 Hoechst Ag Process for the manufacture of benzimidazolones
US3822261A (en) * 1972-10-30 1974-07-02 Dow Chemical Co 5,6-dihalo-2-fluoroalkyl-1h-imidazo(4,5-b)pyrazines
GR72941B (enExample) * 1978-10-20 1984-01-16 Lilly Co Eli
US4210647A (en) * 1979-06-18 1980-07-01 Eli Lilly And Company Antiviral combinations
JPS597175A (ja) * 1982-07-01 1984-01-14 メルク・エンド・カムパニ−・インコ−ポレ−テツド 放射線治療用添加剤として有用な、クロロニトロアミノピラジン及びアルキルアミノピラジンのアミノとアミド誘導体
GB8722488D0 (en) * 1987-09-24 1987-10-28 Fujisawa Pharmaceutical Co Imidazopyridine compound
DK0647137T3 (da) * 1992-06-22 2008-12-08 State Of Oregon Through Oregon Glycinreceptorantagonister og anvendelse deraf
IL112235A (en) * 1994-01-03 2000-06-29 Acea Pharm Inc 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
JP2003520271A (ja) * 2000-01-24 2003-07-02 メルク エンド カムパニー インコーポレーテッド αｖインテグリン受容体拮抗薬
US6538010B1 (en) * 2000-11-08 2003-03-25 Research Triangle Institute Compounds and methods for promoting smoking cessation
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
CN101155782B (zh) * 2005-04-01 2011-05-04 大鹏药品工业株式会社 以吡啶衍生物为有效成分的放射线治疗增强剂
WO2006106984A1 (ja) * 2005-04-01 2006-10-12 Taiho Pharmaceutical Co., Ltd. ピリジン誘導体を有効成分とする放射線治療増強剤
JP2010500372A (ja) * 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
CA2663856A1 (en) 2006-09-28 2008-04-10 Exelixis, Inc. Jak-2 modulators and methods of use
CN101611007A (zh) * 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
KR101712576B1 (ko) * 2008-11-10 2017-03-06 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
WO2011026219A1 (en) * 2009-09-01 2011-03-10 Lu qing-bin Combination therapy for cancer comprising a platinum -based antineoplastic agent and a biocompatible electron donor
US8962631B2 (en) * 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
GB201017345D0 (en) * 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists

Also Published As

Publication number Publication date
BR112015014855A2 (pt) 2017-07-11
US9655965B2 (en) 2017-05-23
EP2935215B1 (en) 2019-11-13
JP6321673B2 (ja) 2018-05-09
CN105164107A (zh) 2015-12-16
KR20150120953A (ko) 2015-10-28
WO2014094178A1 (en) 2014-06-26
AU2013362757A1 (en) 2015-07-30
EP2935215A1 (en) 2015-10-28
JP2016504325A (ja) 2016-02-12
EP2935215A4 (en) 2016-10-26
MX2015008010A (es) 2016-04-26
AU2013362757B2 (en) 2018-06-14
US20150343059A1 (en) 2015-12-03
KR102278760B1 (ko) 2021-07-20
CN105164107B (zh) 2017-12-05
CA2895526A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
US9655965B2 (en) Radiosensitizer compounds for use in combination with radiation
US12208141B2 (en) Anti-cancer nuclear hormone receptor-targeting compounds
CA2926571C (en) Non-platinum-based anti-cancer compounds for use in targeted chemotherapy
WO2008033440A2 (en) Treatment of hyperproliferative diseases with anthraquinones
US9750809B2 (en) Cancer treatment
TW202108570A (zh) 抗癌核荷爾蒙受體標靶化合物
JP2008531720A (ja) 過剰増殖疾患のアントラキノンによる治療
WO2026008715A1 (en) Mitochondrially-targeted antioxidant compound for use in radiation therapy
Tjarks et al. Albert H. Soloway, Rolf F. Barth, Liang Liu

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260804